Long term, open-label safety study of oral almotriptan malate 12.5 mg in the treatment of migraine in adolescents.

Trial Profile

Long term, open-label safety study of oral almotriptan malate 12.5 mg in the treatment of migraine in adolescents.

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Apr 2014

At a glance

  • Drugs Almotriptan (Primary)
  • Indications Migraine
  • Focus Adverse reactions
  • Sponsors Janssen Inc
  • Most Recent Events

    • 30 Mar 2010 Actual patient number (447) added as reported by ClinicalTrials.gov.
    • 29 Sep 2008 Actual end date (December 2007) added as reported by CT.gov
    • 29 Sep 2008 Status changed from active, no longer recruiting to completed as reported by CT.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top